338840
Y-Biologics, Inc., an antibody therapeutics development company, engages in the research and development of immuno-oncology drugs and antibody drugs. The company develops YBL-006, a PD-1 immune-oncology agent that is phase 1 clinical stage for the treatment of solid tumor. It also develops immunoregulatory monoclonal antibodies, such as YBL-011 and AR062 for the treatment of solid cancers; AR166,… Read more
338840 (338840) - Net Assets
Latest net assets as of March 2025: ₩16.68 Billion KRW
Based on the latest financial reports, 338840 (338840) has net assets worth ₩16.68 Billion KRW as of March 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩19.85 Billion) and total liabilities (₩3.17 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩16.68 Billion |
| % of Total Assets | 84.03% |
| Annual Growth Rate | 22.18% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 56.0 |
338840 - Net Assets Trend (2022–2024)
This chart illustrates how 338840's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for 338840 (2022–2024)
The table below shows the annual net assets of 338840 from 2022 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩18.36 Billion | -21.58% |
| 2023-12-31 | ₩23.41 Billion | +90.42% |
| 2022-12-31 | ₩12.29 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to 338840's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2731274268000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | ₩7.39 Billion | 40.27% |
| Other Components | ₩131.26 Billion | 715.06% |
| Total Equity | ₩18.36 Billion | 100.00% |
338840 Competitors by Market Cap
The table below lists competitors of 338840 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Runben Biotechnology Co Ltd Ordinary Shares - Class A
SHG:603193
|
$243.86 Million |
|
Manorama Industries Limited
NSE:MANORAMA
|
$243.87 Million |
|
Circassia Group Plc
OTCGREY:CSSPF
|
$243.88 Million |
|
NIIT LEARNING SYSTEMS LTD
NSE:NIITMTS
|
$243.88 Million |
|
Tristel PLC
PINK:TSNLF
|
$243.69 Million |
|
ADVA Optical Networking SE
PINK:ADVOF
|
$243.68 Million |
|
389650
KQ:389650
|
$243.63 Million |
|
Heba Fastighets AB Series B
LSE:0GNV
|
$243.62 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in 338840's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 23,408,461,010 to 18,355,782,230, a change of -5,052,678,780 (-21.6%).
- Net loss of 6,441,689,680 reduced equity.
- Share repurchases of 201,227,500 reduced equity.
- Other factors increased equity by 1,590,238,400.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-6.44 Billion | -35.09% |
| Share Repurchases | ₩201.23 Million | -1.1% |
| Other Changes | ₩1.59 Billion | +8.66% |
| Total Change | ₩- | -21.58% |
Book Value vs Market Value Analysis
This analysis compares 338840's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 27.30x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 38.24x to 27.30x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-12-31 | ₩886.51 | ₩33900.00 | x |
| 2023-12-31 | ₩1585.65 | ₩33900.00 | x |
| 2024-12-31 | ₩1241.72 | ₩33900.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently 338840 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -35.09%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -111.78%
- • Asset Turnover: 0.27x
- • Equity Multiplier: 1.18x
- Recent ROE (-35.09%) is above the historical average (-92.41%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | -152.97% | -453.06% | 0.14x | 2.39x | ₩-20.03 Billion |
| 2023 | -89.16% | -599.90% | 0.11x | 1.29x | ₩-23.21 Billion |
| 2024 | -35.09% | -111.78% | 0.27x | 1.18x | ₩-8.28 Billion |
Industry Comparison
This section compares 338840's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $209,689,906,881
- Average return on equity (ROE) among peers: -10.47%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| 338840 (338840) | ₩16.68 Billion | -152.97% | 0.19x | $243.70 Million |
| ORIENTBIO Inc. (002630) | $67.35 Billion | -2.60% | 1.21x | $28.10 Million |
| Green Cross (005250) | $282.15 Billion | 18.83% | 0.53x | $228.88 Million |
| Green Cross Holdings Preference Shares (005257) | $1.44 Trillion | 3.01% | 0.78x | $410.72 Million |
| Pharmicell (005690) | $9.90 Billion | -119.73% | 2.00x | $438.14 Million |
| GeneOne Life Science Inc (011000) | $39.74 Billion | 0.00% | 0.49x | $53.78 Million |
| HLB Co. Ltd (028300) | $77.24 Billion | -21.40% | 1.44x | $4.11 Billion |
| Daesung Microbiological Labs. Co. Ltd (036480) | $25.09 Billion | 18.13% | 0.29x | $14.92 Million |
| Seoulin Bioscience Co.Ltd (038070) | $51.49 Billion | 4.00% | 0.38x | $27.72 Million |
| Hyundai Bioscience Co. Ltd (048410) | $39.30 Billion | 0.00% | 0.56x | $899.28 Million |
| iNtRON Biotechnology Inc (048530) | $64.96 Billion | -4.91% | 0.37x | $83.99 Million |